For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Adial Pharmaceuticals, Inc. (ADIL) one of those stocks right now? A quick glance at the company’s year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adial Pharmaceuticals, Inc. is one of 1160 companies in the Medical group. The Medical group currently sits at #8 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Adial Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ADIL’s full-year earnings has moved 0.8% higher. This signals that analyst sentiment is improving and the stock’s earnings outlook is more positive.
According to our latest data, ADIL has moved about 0.4% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 5.3% on average. This means that Adial Pharmaceuticals, Inc. is performing better than its sector in terms of year-to-date returns.
Albireo Pharma (ALBO) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 14.6%.
In Albireo Pharma’s case, the consensus EPS estimate for the current year increased 1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adial Pharmaceuticals, Inc. belongs to the Medical – Biomedical and Genetics industry, which includes 538 individual stocks and currently sits at #108 in the Zacks Industry Rank. Albireo Pharma is also part of the same industry.
Adial Pharmaceuticals, Inc. and Albireo Pharma could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.
See these 7 breakthrough stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report